Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1.

Filippo Montemurro,Paul Ellis,Antonio Anton,Rachel Wuerstlein,Suzette Delaloge,Jacques Bonneterre,Nathalie Quenel-Tueux,Sabine C Linn,Natsumi Irahara,Margarita Donica,Nicolas Lindegger,Carlos H Barrios

European Journal of Cancer（2019）

引用 76|浏览36

暂无评分

摘要

•KAMILLA is the largest cohort of T-DM1–treated patients studied to date (N = 2002).•Results support continued T-DM1 use in HER2-positive advanced breast cancer.•KAMILLA patients represent a broader population than previous registration studies.•T-DM1 was safe, tolerable and efficacious in HER2-positive advanced breast cancer.•Median progression-free and overall survival were 6.9 and 27.2 months, respectively.

查看译文

关键词

Ado-trastuzumab emtansine,Receptor, ErbB-2,Receptor, epidermal growth factor,Drug-related side effects and adverse reactions,Malignant neoplasm of breast,Clinical trial, Phase III

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要